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Lower affinity for substrate for extrarenal synthesis of calcitriol in
chronic uremia. Previous studies from our laboratory have shown that
anephric patients have very low, but detectable, levels of l,25(OH)2D3
(calcitnol) that can be increased to normal by administration of large
doses of 25(OH)D3. The report of la-hydroxylase activity in pig liver
with an affinity for substrate significantly lower than that of the renal
enzyme, led us to use the rat as an experimental model to further clarify
the need of supraphysiological levels of 25(OH)D3 to correct calcitriol
deficiency in chronic uremia. We have measured 1 ,25(OH)2D3 produc-
tion by rat liver. Cytosol free liver homogenates (CFH) from normal
rats were incubated with 25(OH)D3 and the production of I ,25(OH)2D3
was measured using the thymus radioreceptor assay after solid phase
Cl8 extraction and HPLC purification of the samples. 1 ,25(OH)2D3
production was linear up to 30 minutes and a CFH protein concentra-
tion up to 20 mg. Saturability was attained for a substrate concentration
of approximately 60 LM. Ketoconazole, a cytochrome P450 inhibitor,
blocked calcitriol production in a dose dependent fashion. Total inhi-
bition of the liver la-hydroxylase was achieved with 180 M ketocon-
azole. We next compared the kinetics of the I a-hydroxylases of normal
and uremic rat livers. Maximal velocities were not statistically different
(139.6 22.3 pg/mg/mm for normals and 217.1 73.3 pg/mg/mm for
uremic rats). However, the apparent Km was 35.9 3.2 tM for uremic
animals, significantly higher (P  0.001) than that of normal rats (16.6
0.7 SM). These results demonstrate that: (1) la-hydroxylase is ex-
pressed in rat livers; (2) the liver enzyme appears to be a cytochrome
P450 mixed function oxidase; (3) the affinity of the liver enzyme for
25(OH)D3 is significantly reduced in uremia, a finding which may
explain the need of supraphysiological levels of substrate to normalize
serum calcitriol in anephric humans.
In the past decade, there has been increasing evidence that
the kidney is not unique in metabolizing 25(OH)D3 to
1 ,25(OH)2D3. Previous studies in our laboratory have shown
that anephric dialysis patients have low basal serum concentra-
tions of calcitriol (5.5 1.2 pg/mi) which suggest the existence
of extrarenal production of calcitriol [1]. In these patients, a
significant correlation between the circulating levels of
25(OH)D3 and 1 ,25(OH)2D3 was found. Their serum
l,25(OH)2D3 increased to normal levels only when serum
25(OH)D3 approached supraphysiological concentrations. This
suggested a lower affinity or a decreased availability of sub-
strate to the extrarenal 1 a-hydroxylase(s).
In the last ten years numerous reports have shown the
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capacity of different cells/tissues to synthesize calcitriol in vitro
[2—11]. Recently, Hollis demonstrated 1 a-hydroxylase activity
in porcine hepatic tissue [12]. The Km of the liver enzyme (17
ILM) is significantly higher than that of the pig (445 nM) [13] and
rat renal (890 nM) I a-hydroxyiases [14]. The lower affinity for
25(OH)D3 of the hepatic 1 a-hydroxylase could account for the
need of supraphysiological 25(OH)D3 levels to normalize serum
calcitriol in anephric individuals.
To further investigate this possibility, we have examined the
rat as an experimental model for hepatic 1 ,25(QH)2D3 produc-
tion. We have confirmed that 1 a-hydroxylase is expressed in
the liver of normal rats, and we have characterized the kinetic
of this enzyme. We compared the properties of the hepatic
1 a-hydroxylase in normal rats to that in rats with chronic renal
failure.
Methods
25(OH)D3 and i,25(OH)2D3 were provided by Dr. Milan
Uskokovic (Hoffman-LaRoche, Nutley, New Jersey, USA).
1 ,25(OH)2[26,27-methyl-3H]cholecalciferol (SA: 160 to 180 Ci!
mmol) and 25-hydroxy-[26,27-methyl-3H]cholecalciferol (SA:
10 to 20 Ci/mmoi) were obtained from Amersham (Arlington
Heights, Illinois, USA). Dithiothreitol, N,N'-diphenylethyiene-
diamine, nicotinamide adenine dinucleotide phosphate and
isocitrate were purchased from Sigma Chemical Co. (St. Louis,
Missouri, USA). Coomassie blue protein assay reagent was
obtained from Bio-Rad (Richmond, California, USA); C18
cartridges and all HPLC solvents from Fischer Scientific (Fair
Lawn, New Jersey, USA).
Three-month old female Sprague-Dawley rats, 200 to 320
grams body weight, were fed a normal diet (#5001, Ralston-
Purina, St. Louis, Missouri, USA), containing 1.0% calcium
and 0.4% phosphorus. Uremia was induced by 5/6 nephrec-
tomy. Seven to eight weeks after surgery the rats were sacri-
ficed. The livers were removed for further preparation and the
serum was retained for blood chemistry determinations.
The livers were perfused with ice-cold isotonic NaCI, minced
and homogenized in four volumes of ice-cold buffer (50 mM;
Na2HPO4 [pH = 7.4]; 0.25 M sucrose and 0.5 mri EDTA) using
a polytron PT2O disrupter (Kinematica, Switzerland). Five
milliliter aliquots of homogenate were stored at —70°C until
assayed. Immediately before assaying, the jver homogenates
where thawed and centrifuged at 100,000 x g for one hour, as
described by Hollis [12]. Cytosol-free homogenates were pre-
pared by resuspending the resulting pellets to the original
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volume using a buffer containing 50 mi Na2HPO4 (p1-I 7.4);
125 m sucrose; 5 msi KCI; 2 mM MgC12; 2 mM isocitrate; 1 mM
NADPH; 3 mi EDTA; 1 mivi DTT; 10 M N,N' diphenyleth-
ylenediamine (DPED) to prevent free radical generation. The
protein concentration of the CFH was measured by the method
of Bradford [15] with ovalbumin as the standard.
The CFH was incubated in twelve-well plates at 37°C in an
atmosphere containing 95% air, 5% CO2. The final assay
incubation volume was 2 ml. The reaction was initiated by
adding 25(OH)D3 in 20 jsl ethanol to the wells and was termi-
nated by adding 2 ml acetonitrile. Approximately 1000 cpm of
[3H]-1,25(OH)2D3 were added to each well to estimate recov-
eries. The vitamin D metabolite fraction was obtained by C18
cartridge extraction using the procedure described by Reinhardt
et a! [16]. The fraction eluting with acetonitrile was dried under
nitrogen and subjected to normal phase HPLC, using a Zorbax-
Sil column (Phenomenex, St. Torrance, California, USA) and
methylene chloride:isopropanol (96:4) at a flow rate of 2 mllmin.
The 1 ,25(OH)2D3 fraction was collected, dried under nitrogen
and resuspended in 200 l ethanol. Average recoveries were 60
to 80%. 1 ,25(OH)2D3 production was quantitated using the calf
thymus radioreceptor assay [16]. In order to confirm the iden-
tity of the putative 1 ,25(OH)2D3, the 1 ,25(OH)2D3 fraction from
four samples, obtained from the HPLC system described
above, was subjected to two additional HPLC systems: (1)
normal phase HPLC using hexane:isopropanol (93:7) at 2
ml/min flow rate, and (2) reverse phase HPLC using a Zorbax-
ODS column (DuPont mc, Wilmington, Delaware, USA), with
methanol:water (80:20) at 2 mi/mm as solvent. The 1 ,25(OH)2D3
fraction was again dried under nitrogen, resuspended in 200 d
ethanol and quantitated using the radioreceptor assay of Rein-
hardt et al [16].
Zero time controls for endogenous 1 ,25(OH)2D3 present in
the CFH were performed by adding acetonitrile to the reaction
buffer before the CFH and the substrate. The 1 ,25(OH)2D3
levels measured in these controls were used to correct
1 ,25(OH)2D3 production of all 1 ,25(OH)2D3 determinations.
Negative controls for non-enzymatic oxidation of 25(OH)D3
consisting of both CFH boiled for three minutes and plates
without protein were submitted to the same 25(OH)D3 incuba-
tion reaction. 1 ,25(OH)2D3 levels in these negative controls did
not differ from the zero time controls described above, and
represented 0 to 3% of the maximal 1 ,25(OH)2D3 production
(average Vmax).
To determine Km and Vmax, liver CFH were incubated (in
duplicate) with five different substrate concentrations from 0 to
180 /LM 25(OH)D3 and the rate of 1,25(OH)2D3 production was
measured. Km and maximal velocity were obtained from a
single plot of the data.
The amount of DBP in the CFH of normal and uremic animals
was estimated by quantitation of maximal specific 25(OH)D3
binding. We measured competitive displacement of [3H]-
25(OH)D3 from CFH by radioinert 25(OH)D3 using equilibrium
ligand-binding conditions [17]. Two hundred and forty fmoles of
[3H]-25(OH)D3 dissolved in 10 1u1 ethanol was mixed either with
10 d ethanol or with 200 molar excess (48,000 fmol) radioinert
25(OH)D3 in 10 l ethanol. Five hundred microliters of CFH
diluted 1:10 or 1:20 [a concentration range which includes those
used to determine 1 ,25(OH)2D3 production] with freshly pre-
pared barbital-acetate buffer (0.05 M Na barbital-acetate, pH =
Time, minutes
Fig. 1. Time course for 1,25(OH)2D3 production by rat liver CFH at a
substrate concentration of 60 oi. Each point represents the mean of
duplicate determinations.
8.6, 12 mtvi dithiothreitol, 0.1% BSA) were added and the
samples were incubated at 0°C for two hours. Two hundred
microliters of dextran-charcoal (2% Norit Charcoal Decoloriz-
ing Neutral, 2% T70 dextran in barbital-acetate buffer freshly
prepared and stirred well before addition) was used to separate
bound and free [3H]-25(OH)D3. The assay tubes were vortexed
and centrifuged at 1500 x g for 15 minutes at 0 to 5°C. Five
hundred microliters of supernatant were collected and counted
for tritium. The specific binding of 25(OH)D3 to DBP [and
possibly other 25(OH)D3 binding proteins present in the CFHJ
was calculated using the formula 0 — E/T — E, where E is the
cpm in the samples containing an excess of nonradioactive
25(OH)D3, T is total counts, and 0 is the cpm in the samples
containing no radioinert 25(OH)D3.
Creatinine was determined using a Multistat 111 Plus (Instru-
mentation Laboratories, Boston, Massachusetts, USA). Cal-
cium was determined by atomic absorption spectrophotometry
(Perkin-Elmer, Model 503, Norwalk, Connecticut, USA). Se-
rum l,25(OH)2D3 was measured following the extraction pro-
cedure developed by Hollis [18] and the receptor assay of
Reinhardt et al [16].
Student's t-test was used to quantitate statistical differences
between experimental groups. Values were expressed as the
mean SEM.
Results
The time course for conversion of 25(OH)D3 to 1 ,25(OH)2D3
is shown in Figure 1. The reaction was linear up to 30 minutes.
A 10 minute incubation was used in all further assays unless
otherwise specified. Protein dependence is depicted in Figure 2.
l,25(OH)2D3 production was linear when amounts up to 20 mg
protein of the CFH were used; 7.5 mg of protein were used in
further experiments.
1 ,25(OH)2D3 production versus substrate concentration is
shown in Figure 3. Saturation was reached at approximately 60
/LM 25(OH)D3.Quantitation of l,25(OH)2D3 production resulted in an aver-
age of 7.1 ng 1,25(OH)2D3 (average recovery: 69.2%) for the
samples subjected to one HPLC purification and a mean of 6.9
cs.
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ng of 1 ,25(OH)2D3 (average recovery: 60.7%) for those under-
going three HPLC purification steps. This suggests that the
compound eluting with [3H1-1 ,25(OH)2D5 using the methylene
chloride:isopropanol system is authentic 1 ,25(OH),D3. In all
subsequent experiments, determination of 1 ,25(OH)2D3 pro-
duction was performed after only one HPLC purification using
methylene chloride:isopropanol.
Figure 4 shows the dose dependent inhibition of 1 ,25(OH)2D3
production by ketoconazole. Ketoconazole, at a concentration
of 2.5 j.M inhibited 1 ,25(OH)2D3 production by 23.6%. Total
inhibition was achieved at a concentration of 180 JLM.
Km and 1max of rat liver 1 a-hydroxylase were measured in
seven normal and seven uremic rats. The mean SEM of body
weight, and serum levels of calcium (Ca), phosphorus (P), blood
urea nitrogen (BUN) and creatinine are shown in Table 1. There
were no significant differences in the serum calcium and phos-
phorus between the two groups. As expected, in uremic ani-
-
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BUN mg/dl
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1,25(OH)2D3 pg/mi
262 11.2
10.1 0.1
4.6 0.5
14.9 1.3
0.6 0.03
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228.1 1o.3
10.3 0.2
5.5 1.5
46.5 75b
1.3 0.1"
14.8 ,9b
mals, BUN and creatinine were significantly higher and serum
1 ,25(OH)2D3 significantly lower than in normal rats. Individual
values for Km and Vmax are shown in Table 2. In normal rats,
average Km and Vmax were 16.6 0.7 p.M and 139.6 22.3 pg
of 1 ,25(OH)2D3/mg protein/mm, respectively. In chronic ure-
mia, the apparent Km was 35.9 3.2 p.M, significantly higher (P
0.001) than that of normal animals. The average value for
Vmax in uremic rats was 217.0 73.3 pg 1,25(OH)2D3fmg
protein/minute. Due to the variation in Vmax determinations in
chronic renal failure, there was no significant difference in this
parameter between normal and uremic rats.
There was no significant difference in the maximal specific
binding of 25(OH)D3 to DBP and other 25(OH)D3 binding
proteins in the CFH from normal and uremic animals (normal:
144.0 6.0 fmol 25(OH)D1/mg prot. (N = 6) vs. uremic: 141.0
6.5 fmol 25(OH)D3/mg protein, N = 5).
Discussion
Extrarenal generation of calcitriol in humans has been con-
clusively demonstrated in sarcoidosis [19], pregnancy [20] and
chronic renal failure [1]. In chronic uremia, the contribution of
extrarenal sources of calcitriol to serum 1 ,25(OH)2D3 concen-
tration is insignificant as proven by the low circulating levels of
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Fig. 4. The effect of ketoconazole concentration on the production of
1,25(OH)2D3 by rat liver CFH. Bars represent the mean of duplicate
determinations.
Table I. Body weight and serum concentrations of calcium,
phosphorus, BUN, creatinine and I ,25(OH)2D3 in normal and uremic
rats
20
E
10
I0
LU
c'j
0
Protein, mg
Fig. 2. Effect of protein concentration on I ,25(OH)2D3 production by
rat liver CFH. Substrate concentration was 60 /LM. Each point repre-
sents the mean of duplicate determinations.
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Fig. 3. Effect of substrate concentration on I,25(OH)2D3 production
by rat liver CFH. Each point represents the mean of duplicate
determinations.
Ketoconazole, p.M
25(OH)D3, LM
Values are expressed as mean SEM.
a p < 0.05
"P < 0.01
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Table 2. Individual values for Km (SM) and 'max [pg of 1 ,25(OH)2D3/
mg prot/min] determinations in liver homogenates from 7 normal and
' uremic rats
Km Vmax
Normal Uremic Normal Uremic
19 21 144 65.3
17 29 104 112
16 38 197 547
16 36 241 433
17 46 82 179
18 42 110 134
13 38 98 49
the sterol at physiological concentrations of 25(OH)D3. How-
ever, extrarenal production can correct serum calcitriol after
25(OH)D3 supplementation [1]. Our laboratory has been inter-
ested in defining the location and regulation of the extrarenal
sources of calcitriol in chronic uremia. We have reported that
peripheral blood mononuclear phagocytes from normal volun-
teers constitutively express 1 a-hydroxylase activity, and that
the activity of the enzyme is enhanced in patients undergoing
hemodialysis [21]. However, the Km of the enzyme of normal
macrophages is similar to that of the renal enzyme. Thus, unless
the Km for 25(OH)D3 of the enzyme in macrophages is altered
in chronic uremia, it is not clear why supraphysiological levels
of substrate are required to normalize serum calcitriol in
anephric patients. The amount of blood required to examine the
Km of macrophage 1 a-hydroxylase has been a limiting factor to
further characterize this issue in patients with CRF and has led
us to a search for an appropriate experimental model.
The report of hepatic 1 a-hydroxylase activity in pigs with an
affinity for 25(OH)D3 significantly lower than that of the renal
enzyme [12] prompted us to examine the rat liver as a site of
extrarenal synthesis of 1 ,25(OH)2D3.
We found that rat hepatic tissue can convert 25(OH)D3 to a
metabolite that, based on chromatographic properties and on its
ability to bind the call thymus vitamin D receptor, appears to be
1 ,25(OH)D3. We used the free radical scavengers, DPED and
EDTA [22], in the incubation media, which suggests that
calcitriol production by hepatic tissue is not mediated by free
radical generation. Total inhibition of the rat liver enzyme by
ketoconazole, a cytochrome P450 inhibitor that interacts with
the heme iron of the cytochrome [23], suggests that the rat
hepatic la-hydroxylase, similar to the renal enzyme, is a
cytochrome P450 mixed function oxidase.
Total inhibition of 1 ,25(OH)2D3 production in mitochondrial
and microsomal subcellular fractions of pig liver with 2 M
ketoconazole was reported by Hollis [12]. The requirement for
higher amounts of ketoconazole in our experimental conditions
can be attributed to (1) less access of ketoconazole to the
1 a-hydroxylase in homogenates than to pure subcellular or-
ganelles or (2) difficulties in obtaining a homogeneous distribu-
tion of ketoconazole in the wells compared to the culture tubes
used by Hollis.
Kinetic analysis of the 1 a-hydroxylase of rat liver showed a
Km of 16.6 0.7 M similar to that reported for the enzyme in
pig liver. However, there was a marked discrepancy between
the Vma,, obtained by us and that reported by Hollis. This could
be due to species differences (rat vs. pig) or to the use of
different subcellular fractions (CFH vs. mitochondria). While
Hollis showed no saturability of the enzyme with increasing
substrate concentrations in the microsomal fraction, in our
studies, enzyme saturability was reached in every liver CFH
examined. Assessment of the individual contribution of differ-
ent subcellular fractions in the rat will require further studies.
The lower affinity of the hepatic enzyme for 25(OH)D3 could
represent an appealing explanation for the need of increased
25(OH)D3 levels to normalize serum 1 ,25(OH)2D3 concentra-
tions in the absence of renal mass. We next examined whether
chronic uremia further affects the affinity for substrate of the
hepatic 1 a-hydroxylase. In uremic rats, the Km of the hepatic
enzyme was significantly higher than in normal animals without
significant differences in Vmax between the two groups. It is
possible that uremia could affect in a different manner the
expression of the la-hydroxylase andlor the accessibility of
substrate to each subcellular fraction. Further examination of
individual organelle preparations is required to determine if the
increased Km in uremic livers is the result of altered kinetics in
the mitochondrial and/or microsomal fractions. The observed
difference in Km between the two groups of animals cannot be
attributed to differences in the binding of 25(OH)D3 to DBP
since the specific binding of 25(OH)D3 to CFH was not different
between normal and uremic rats. Serum level of DBP has been
reported to remain constant in patients with varying degrees of
renal failure [24], and our in vitro assessment of DBP agrees
with those findings. It is important to mention that a 10-fold
variation in Vmax was observed in uremic rats. A similar range
of Vmax values (40-fold variation) was reported for the 1 a-
hydroxylase of pulmonary alveolar macrophages in patients
with sarcoidosis [25]. Our findings of increased Km in uremic
rats with no significant modification of Vmax suggest a compet-
itive inhibition of the hepatic la-hydroxylase. These observa-
tions agree with Hsu and collaborators [26, 27] that several
uremic toxins can suppress the renal 1 ,25(OH)2D3 production in
vivo and in vitro. Extrapolation of the uremic rat liver hydrox-
ylase findings to our previous observation in anephric humans
suggests that the accumulation of "uremic toxins" during the
progression of renal failure may impair the access of 25(OH)D3
to the active site of the extrarenal enzyme, thus requiring higher
levels of 25(OH)D3 to overcome the inhibition and restore
normal 1 ,25(OH)2D3 levels in circulation.
Further studies are required for a precise location of the cell
type (hepatocytes, Kupifer cells, endothelial cells or lipocytes)
responsible for calcitriol generation by the liver. Modulation of
the liver enzyme could be an important therapeutic tool to
correct the abnormal vitamin D metabolism of chronic uremia.
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